Is MOTS-c FDA Approved?

The short answer

No. As of 2026, MOTS-c has no FDA approval for any use. There is no approved drug that contains it, it is not marketed as (and does not qualify as) a dietary supplement, and it is sold as a research-use-only chemical, explicitly not for human consumption. In regulatory terms, MOTS-c has simply never gone through the process that would let the FDA say anything about whether it is safe or effective.

That single fact is the whole answer, but it is easy to misread. "Not FDA approved" is often treated as if it means "banned" or "proven unsafe." It means neither. It means the evidence and the formal review that approval requires do not exist for MOTS-c. To see how this compares across peptides, our companion piece is BPC-157 FDA approved? walks through the same logic for a more widely discussed compound.

What "FDA approved" actually means

FDA approval is a specific legal milestone, not a general seal of quality. For a drug, a sponsor must submit a new drug application (NDA) — or a biologics license application — backed by controlled clinical trials that establish the product's safety and effectiveness for a defined use, along with evidence that it can be manufactured to consistent quality. The FDA reviews that dossier and either approves the product for that specific indication or does not.

MOTS-c has none of this. No sponsor has taken it through human clinical trials to approval, so there is no NDA, no approved label, and no approved indication. It also cannot slip in through the supplement door: peptides like MOTS-c do not meet the statutory definition of a dietary ingredient, so "supplement" is not a lawful category for it. That leaves only the research-use-only channel — the distinction we explain in research peptides vs prescription peptides.

It also helps to understand where a research peptide physically comes from. What is sold is a bulk drug substance — the raw active ingredient in powder form, before any finished, approved product exists. We define that term in what does "bulk drug substance" mean, and it is central to why unapproved peptides sit outside normal medical supply chains.

Where MOTS-c stands in research

MOTS-c is a 16-amino-acid mitochondrial-derived peptide — unusual because its coding sequence lies within the mitochondrial genome rather than the nucleus. In the laboratory it is studied for its association with the energy-sensing enzyme AMPK, glucose metabolism, and exercise-related adaptation. That makes it scientifically interesting, but the work is overwhelmingly preclinical: cell cultures and animal models rather than large, controlled human trials.

This early stage is precisely why approval does not exist. Approval sits at the *end* of a long evidence pipeline — discovery, preclinical work, then multiple phases of human trials. A peptide can be a legitimate and active area of research while being nowhere near that finish line. For the underlying biology and citations, see the full MOTS-c research profile and the broader research library.

Why "not approved" is not the same as "illegal"

The most common confusion is treating "unapproved" and "illegal" as synonyms. They describe different systems. Approval is about whether the FDA has reviewed a product and cleared it for a medical use. Whether a substance is a controlled substance is a separate question governed by the Controlled Substances Act. MOTS-c is not a scheduled controlled substance, and simply lacking FDA approval does not make possession of a research chemical a crime.

What the unapproved status *does* mean is that MOTS-c cannot be lawfully sold or marketed for human use, cannot be prescribed as an approved medicine, and carries no FDA assurance of purity, potency, or safety. Any product claiming otherwise is a red flag. The honest framing is that MOTS-c's status is an absence of evidence and review, not a government verdict — a theme we develop in why peptides are research-only.